Tumors with TSC mutations are sensitive to CDK7 inhibition through NRF2 and glutathione depletion

© 2019 Zarei et al. http://www.rupress.org/terms/https://creativecommons.org/licenses/by-nc-sa/4.0/This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see http://www.rupress.org/terms/). After six months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 4.0 International license, as described at https://creativecommons.org/licenses/by-nc-sa/4.0/).

Author Information

Mahsa Zarei,1,2,*
Heng Du,1,*
Amin H. Nassar,1
Rachel E. Yan,1
Krinio Giannikou,1
Sneha H. Johnson,2
Hilaire C. Lam,3
Elizabeth P. Henske,3
Yubao Wang,4
Tinghu Zhang,4,5
John Asara,6 and
David J. Kwiatkowski1 ⇑

¹Cancer Genetics Laboratory, Pulmonary and Critical Care Medicine, Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA
²Department of Veterinary Physiology and Pharmacology, College of Veterinary Medicine and Biomedical Sciences, Texas A&M University, College Station, TX
³Pulmonary and Critical Care Medicine, Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA
⁴Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA
⁵Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA
⁶Division of Signal Transduction, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA